CY1125117T1 - Ενωσεις μορφολινυλπυριδονης - Google Patents
Ενωσεις μορφολινυλπυριδονηςInfo
- Publication number
- CY1125117T1 CY1125117T1 CY20221100283T CY221100283T CY1125117T1 CY 1125117 T1 CY1125117 T1 CY 1125117T1 CY 20221100283 T CY20221100283 T CY 20221100283T CY 221100283 T CY221100283 T CY 221100283T CY 1125117 T1 CY1125117 T1 CY 1125117T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- morpholinylpyridone
- formula
- diseases
- diabetes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17187567 | 2017-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1125117T1 true CY1125117T1 (el) | 2024-12-13 |
Family
ID=59686888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20221100283T CY1125117T1 (el) | 2017-08-23 | 2022-04-14 | Ενωσεις μορφολινυλπυριδονης |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11560374B2 (https=) |
| EP (2) | EP4056569A1 (https=) |
| JP (2) | JP7199736B2 (https=) |
| KR (1) | KR102732013B1 (https=) |
| CN (3) | CN116462674A (https=) |
| AU (2) | AU2018320419B2 (https=) |
| CY (1) | CY1125117T1 (https=) |
| DK (1) | DK3672962T3 (https=) |
| ES (1) | ES2910157T3 (https=) |
| HR (1) | HRP20220497T1 (https=) |
| HU (1) | HUE058661T2 (https=) |
| IL (3) | IL302077A (https=) |
| LT (1) | LT3672962T (https=) |
| PL (1) | PL3672962T3 (https=) |
| PT (1) | PT3672962T (https=) |
| RS (1) | RS63109B1 (https=) |
| SI (1) | SI3672962T1 (https=) |
| SM (1) | SMT202200169T1 (https=) |
| TW (2) | TW202348601A (https=) |
| WO (1) | WO2019038390A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3200038A1 (en) * | 2020-11-25 | 2022-06-02 | Deciphera Pharmaceuticals, Llc | Anti-viral activity of vps34 inhibitors |
| EP4251165A1 (en) * | 2020-11-25 | 2023-10-04 | Deciphera Pharmaceuticals, LLC | Morpholino derivatives as vsp34 inhibitors for use in the treatment of a viral infection |
| WO2022115562A1 (en) | 2020-11-25 | 2022-06-02 | Deciphera Pharmaceuticals, Llc | Morpholino derivatives as vsp34 inhibitors for use in the treatment of a viral infection |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7820654B2 (en) * | 2004-09-23 | 2010-10-26 | Dr. Reddy's Laboratories Ltd. | Pyrimidine compounds, process for their preparation and compositions containing them |
| WO2011058478A1 (en) * | 2009-11-16 | 2011-05-19 | Pfizer Inc. | Substituted triazolopyrimidines as pde8 inhibitors |
| AU2011346567A1 (en) | 2010-12-21 | 2013-07-25 | Novartis Ag | Bi-heteroaryl compounds as Vps34 inhibitors |
| FR2969612B1 (fr) * | 2010-12-23 | 2013-02-08 | Sanofi Aventis | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one, leur preparation et leur utilisation pharmaceutique |
| DK2655375T3 (en) * | 2010-12-23 | 2015-03-09 | Sanofi Sa | PYRIMIDINON DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF |
| GB201120317D0 (en) | 2011-11-24 | 2012-01-04 | Queen Mary & Westfield College | Screening method |
| FR2992314B1 (fr) | 2012-06-22 | 2015-10-16 | Sanofi Sa | Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique |
| JP6074043B2 (ja) * | 2013-08-29 | 2017-02-01 | 富士フイルム株式会社 | 新規なモルホリン誘導体またはその塩 |
| WO2015108881A1 (en) | 2014-01-14 | 2015-07-23 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| AU2015206652A1 (en) | 2014-01-14 | 2016-08-04 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
| MA39823A (fr) | 2014-04-03 | 2018-01-09 | Janssen Pharmaceutica Nv | Dérivés de pyridine macrocyclique |
| MA39822A (fr) | 2014-04-03 | 2018-02-06 | Janssen Pharmaceutica Nv | Dérivés de pyrimidine bicycle |
| WO2017009751A1 (en) * | 2015-07-15 | 2017-01-19 | Pfizer Inc. | Pyrimidine derivatives |
| AU2017219846B2 (en) | 2016-02-19 | 2021-05-13 | Sprint Bioscience Ab | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes |
| DK3416957T3 (da) * | 2016-02-19 | 2020-09-21 | Sprint Bioscience Ab | 6-heterocyclyl-4-morpholin-4-ylpyridin-2-on-forbindelser anvendelige ved behandlingen af cancer og diabetes |
-
2018
- 2018-08-23 US US16/639,902 patent/US11560374B2/en active Active
- 2018-08-23 TW TW112116474A patent/TW202348601A/zh unknown
- 2018-08-23 KR KR1020207007564A patent/KR102732013B1/ko active Active
- 2018-08-23 RS RS20220357A patent/RS63109B1/sr unknown
- 2018-08-23 SI SI201830624T patent/SI3672962T1/sl unknown
- 2018-08-23 EP EP22153292.2A patent/EP4056569A1/en not_active Withdrawn
- 2018-08-23 CN CN202310448740.0A patent/CN116462674A/zh active Pending
- 2018-08-23 PT PT187591052T patent/PT3672962T/pt unknown
- 2018-08-23 WO PCT/EP2018/072791 patent/WO2019038390A1/en not_active Ceased
- 2018-08-23 DK DK18759105.2T patent/DK3672962T3/da active
- 2018-08-23 HR HRP20220497TT patent/HRP20220497T1/hr unknown
- 2018-08-23 IL IL302077A patent/IL302077A/en unknown
- 2018-08-23 HU HUE18759105A patent/HUE058661T2/hu unknown
- 2018-08-23 TW TW107129499A patent/TWI803511B/zh not_active IP Right Cessation
- 2018-08-23 ES ES18759105T patent/ES2910157T3/es active Active
- 2018-08-23 LT LTEPPCT/EP2018/072791T patent/LT3672962T/lt unknown
- 2018-08-23 SM SM20220169T patent/SMT202200169T1/it unknown
- 2018-08-23 CN CN202310448700.6A patent/CN116444510A/zh active Pending
- 2018-08-23 AU AU2018320419A patent/AU2018320419B2/en not_active Ceased
- 2018-08-23 EP EP18759105.2A patent/EP3672962B1/en active Active
- 2018-08-23 JP JP2020510087A patent/JP7199736B2/ja active Active
- 2018-08-23 PL PL18759105T patent/PL3672962T3/pl unknown
- 2018-08-23 CN CN201880060742.XA patent/CN111108102B/zh active Active
-
2020
- 2020-02-20 IL IL272815A patent/IL272815B/en unknown
-
2022
- 2022-04-14 CY CY20221100283T patent/CY1125117T1/el unknown
- 2022-04-25 IL IL292489A patent/IL292489B2/en unknown
- 2022-12-13 JP JP2022198452A patent/JP2023021268A/ja not_active Ceased
- 2022-12-19 US US18/084,208 patent/US20230234949A1/en not_active Abandoned
-
2023
- 2023-12-22 AU AU2023285995A patent/AU2023285995A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123349T1 (el) | Ενωσεις 6-ετεροκυκλυλ-4-μορφολιν-4-υλπυρiδιν-2-οnhς χρησιμες για τη θεραπεια καρκινου και διαβητη | |
| CY1125245T1 (el) | Ετεροκυκλικες ενωσεις ως αναστολεις ρι3κ-γαμμα | |
| CY1125436T1 (el) | Αναστολεις dna-pk | |
| CY1123561T1 (el) | Ενωσεις χρησιμες ως αναστολεις κινασης | |
| CY1125138T1 (el) | Ενωσεις πυριδυλπυριδονης | |
| EA201991503A1 (ru) | Производные пиразола в качестве ингибиторов malt1 | |
| CY1125047T1 (el) | Διεργασιες για την παρασκευη ενωσεων τυπου οξαθειαζινης | |
| CY1125150T1 (el) | Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου | |
| MY196726A (en) | Fused ring compounds | |
| EA202092907A1 (ru) | Мультиспецифические связывающие белки и их усовершенствования | |
| EA202091484A1 (ru) | 4-азаиндольные соединения | |
| CY1124704T1 (el) | Παραγωγα sobetirome | |
| EA201890857A1 (ru) | Соединения, применимые в качестве иммуномодуляторов | |
| CL2019001740A1 (es) | Novedoso conjugado de amanitina. | |
| EA201791507A1 (ru) | Пирроло- и пиразолопиримидины в качестве ингибиторов убиквитин- специфичной протеазы 7 | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| CY1125169T1 (el) | ΕΝΩΣΕΙΣ ΑΜΙΝΟΠΥΡΑΖΙΝΟ ΔΙΟΛΗΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΡΙ3Κ-γ | |
| CY1125117T1 (el) | Ενωσεις μορφολινυλπυριδονης | |
| JOP20220119A1 (ar) | أجسام مضادة trem2 واستخداماتها | |
| EA201891494A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
| EA201990598A1 (ru) | Высококонцентрированные низковязкие препараты ингибирующего masp-2 антитела, наборы и способы | |
| EA202090014A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA202091477A1 (ru) | Замещенные соединения простых индольных эфиров | |
| UA117364C2 (uk) | Похідні аматоксину | |
| CY1123285T1 (el) | Ενωσεις 6-αρυλ-4-(μορφολιν-4-υλ)-1η-πυριδιν-2-ονης χρησιμες για τη θεραπεια καρκινου και διαβητη |